GlassScriptPhysician profile
Keya Kuhn
NPI 1396908513
$8,448.19
in general payments reported to CMS, 2019-2025
42 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $204 · 2021: $502 · 2022: $1,606 · 2023: $2,092 · 2024: $1,726 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,399.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,427.26 | 2021-2025 | |
| Novo Nordisk INC | $1,026.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $958.96 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $804.16 | 2019-2025 | |
| Lilly USA, LLC | $551.11 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $546.41 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $473.29 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $242.40 | 2019-2024 | |
| Axsome Therapeutics, INC. | $202.15 | 2023-2025 | Auvelity, Symbravo |
| Medtronic, INC. | $171.84 | 2023-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $145.74 | 2022 | |
| Exact Sciences Corporation | $141.65 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.45 | 2019-2024 | Jardiance, Ofev, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $121.11 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.85 | 2019-2025 | Xifaxan |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $116.85 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $115.70 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $111.32 | 2019-2024 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $100.23 | 2019-2022 | |
| Abbott Laboratories | $93.54 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $88.69 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $80.48 | 2025 | |
| Phathom Pharmaceuticals, INC. | $71.98 | 2024-2025 | Voquezna |
| Eisai INC. | $60.13 | 2021-2025 | |
| Lundbeck LLC | $56.28 | 2024-2025 | Vyepti, Rexulti |
| Amarin Pharma, INC. | $53.23 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $47.95 | 2021-2025 | Zoryve |
| Radius Health, INC. | $40.42 | 2023 | Tymlos |
| Dynavax Technologies Corporation | $36.32 | 2023-2025 | Heplisav-B |
| Globus Medical, INC. | $30.66 | 2025 | Senza |
| Verity Pharmaceuticals INC. | $28.68 | 2024 | Tlando |
| Idorsia Pharmaceuticals US INC | $28.55 | 2022-2023 | Quviviq |
| Tempus Ai, INC | $25.88 | 2024 | |
| Edwards Lifesciences Corporation | $25.21 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Takeda Pharmaceuticals U.S.A., INC. | $24.83 | 2019 | |
| Allergan, INC. | $24.63 | 2020 | |
| Celgene Corporation | $24.11 | 2019 | |
| Daiichi Sankyo INC. | $23.92 | 2023 | Injectafer |
| Adlon Therapeutics L.P. | $17.97 | 2021 | |
| Sumitomo Pharma America, INC. | $17.46 | 2024 | Gemtesa |
| Aytu Biopharma, INC. | $17.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.06 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keya Kuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.